Close Menu

NEW YORK ─ MIP Diagnostics is accelerating internal product development of molecularly imprinted polymer (MIP) technology that it believes has advantages over traditional antibodies for diagnostic testing.

The company's MIPs are prepared using a proprietary imprinting process involving the self-assembly of binding monomers around a target to create a novel affinity reagent. The monomers are polymerized to generate a synthetic antibody that targets a binding site on an antigen associated with a medical condition.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.